Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life
- 31 August 2004
- journal article
- clinical trial
- Published by Elsevier BV in Annals of Allergy, Asthma & Immunology
- Vol. 93 (2), 142-146
- https://doi.org/10.1016/s1081-1206(10)61466-4
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticariaAnnals of Allergy, Asthma & Immunology, 2000
- A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticariaJournal of Allergy and Clinical Immunology, 1999
- The extent and nature of disability in different urticarial conditionsBritish Journal of Dermatology, 1999
- The impact of chronic urticaria on the quality of lifeBritish Journal of Dermatology, 1997
- Update on Urticaria and Angioedema (Hives)Allergy and Asthma Proceedings, 1995
- Dermatology in-patient management greatly improves life qualityBritish Journal of Dermatology, 1995
- Chronic UrticariaThe New England Journal of Medicine, 1995
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- How much disability is caused by acne?Clinical and Experimental Dermatology, 1989
- Psoriasis-an index of disabilityClinical and Experimental Dermatology, 1987